Approved indications
Reyvow is FDA-approved for the acute treatment of migraine attacks, with or without aura, in adults; it is not indicated for migraine prevention or for use in pediatric patients.

Off-label uses
There are no widely accepted, well-established off-label uses in routine practice; research of ditans has focused mainly on acute migraine treatment, and any other use would be based on limited or emerging evidence and specialist judgment.

Efficacy expectations and onset
Many people begin to notice pain relief within 1 to 2 hours after taking a dose, and some experience meaningful improvement as early as 30 to 60 minutes; benefit can include reduced headache pain and improvement in bothersome migraine symptoms such as nausea or sensitivity to light and sound.

Typical clinical outcomes
In clinical studies, a significant portion of patients achieved freedom from migraine pain and their most bothersome symptom at 2 hours compared with placebo, though not everyone responds to treatment and some attacks may need additional non-Reyvow measures as directed by a clinician.

Comparison to similar drugs
Compared with triptans, Reyvow lacks strong blood-vessel–constricting effects and may be considered in some patients who cannot use triptans for cardiovascular reasons, but it can cause more dizziness and sedation, carries a driving impairment warning, and like other acute migraine drugs it should not be used too frequently to avoid medication overuse headaches.

Typical adult dosing
For adults, the usual dose is a single oral dose of 50 mg, 100 mg, or 200 mg taken once, as needed, at the onset of a migraine attack; do not take more than one dose in any 24-hour period and do not use it on a daily basis for prevention.

How to take
Swallow the tablet whole with water, with or without food, as soon as you recognize a migraine attack; follow your prescriber’s instructions on which strength to use and how often it is appropriate for you to take the medicine.

Special dosing instructions
Your prescriber may choose a lower starting dose based on your response, other medicines you take, or liver function; because of the risk of drowsiness and dizziness, plan for at least 8 hours after each dose before driving or performing tasks that require full alertness.

Missed-dose guidance
Reyvow is taken only when needed for a migraine attack, not on a fixed schedule, so there is no regular dose to “make up”; if your symptoms have completely passed, do not take an extra tablet "just in case."

Overdose
In case of accidental or intentional overdose, or if someone has taken more than prescribed, seek emergency medical care or contact poison control right away, and do not drive yourself to medical care because of possible severe dizziness or sedation.

Common side effects
Common effects include dizziness, sleepiness (sedation), fatigue, tingling sensations, nausea, and sometimes numbness or a feeling of heaviness; these usually start within a few hours of the dose, are often mild to moderate, and typically resolve as the dose wears off, but they can be strong enough to affect activities such as driving.

Serious or rare adverse effects
Seek urgent medical attention for signs of severe allergic reaction (such as swelling of face, lips, tongue or throat, trouble breathing, or widespread rash), serotonin syndrome when combined with other serotonin-active medicines (symptoms can include agitation, confusion, sweating, fever, fast heartbeat, muscle stiffness, or loss of coordination), or any unusual severe neurological symptoms or loss of consciousness.

Warnings and precautions
Reyvow can significantly impair driving and operating machinery for at least 8 hours after a dose; patients should not drive or engage in hazardous activities during this time, even if they feel well. Use during pregnancy or breastfeeding should be carefully weighed by a clinician, as human data are limited. Safety and effectiveness have not been established in children or adolescents. People with significant liver problems may need extra caution or dose adjustments, and those taking multiple serotonergic medications (including certain antidepressants, migraine drugs, and herbal products like St. John’s wort) require monitoring for serotonin syndrome.

Relative safety profile
Compared with some older migraine drugs that constrict blood vessels, Reyvow may be preferable for certain patients with cardiovascular disease, but its sedating and dizziness effects are more prominent and the driving restriction is stricter than with many other acute migraine therapies.

Reporting side effects and staying updated
Patients in the United States can report suspected side effects to the FDA’s MedWatch program or to the manufacturer, and should check FDA and manufacturer materials or consult their healthcare professional for the latest safety communications and prescribing information.

Drug and supplement interactions
Reyvow can interact with other medicines that affect serotonin, such as many antidepressants (SSRIs, SNRIs, tricyclics, MAOIs), other migraine medicines affecting serotonin, certain pain medicines, and herbal products like St. John’s wort, increasing the risk of serotonin syndrome. It is metabolized in the liver, and strong inhibitors of certain liver enzymes or transporters may change its levels, so your prescriber should review all prescription and nonprescription medicines you take.

Alcohol, food, and other products
Alcohol and other sedating substances (such as some sleep aids, anxiety medicines, or opioids) can increase dizziness and drowsiness when combined with Reyvow, so their use together should be minimized or avoided. There are no major food restrictions, but taking it with alcohol or large amounts of other sedating products is discouraged.

Precautions and conditions
Tell your clinician if you have liver problems, a history of substance misuse, frequent use of other acute migraine medicines, or if you take multiple serotonergic drugs. Although it does not strongly constrict blood vessels, your cardiovascular history still matters when selecting a migraine therapy, and your clinician may combine information about your heart and stroke risk factors with your migraine history when deciding whether Reyvow is appropriate.

Monitoring needs
Routine blood tests are not typically required solely because of Reyvow, but monitoring for symptoms of serotonin syndrome, excessive sedation, or overuse of acute migraine medication is important; your clinician may periodically review your migraine frequency, overall medication list, and functional status (including driving safety) while you are using this drug.

Q: Is Reyvow used to prevent migraines or only to treat them when they happen?
A: Reyvow is approved only for the acute treatment of migraine attacks when they occur; it is not used as a daily preventive medicine.

Q: How long after taking Reyvow do I need to wait before I can drive?
A: You should not drive or operate machinery for at least 8 hours after taking a dose, even if you feel well, because Reyvow can cause significant dizziness and drowsiness.

Q: Can I take Reyvow if triptans did not work well for me?
A: Yes, some people who do not respond to or cannot take triptans may benefit from Reyvow, but response varies, so your healthcare professional will help decide if it is a suitable option for you.

Q: Can I take Reyvow with my antidepressant?
A: Many people use Reyvow with antidepressants, but this combination can increase the risk of serotonin syndrome, so your prescriber should review all your medicines and advise you on warning signs to watch for.

Q: How often is it safe to use Reyvow for migraines?
A: It should not be taken more than once in 24 hours, and like other acute migraine medicines it should not be used too frequently over the month, so your clinician will suggest a maximum number of treatment days and may recommend preventive options if attacks are frequent.

Storage
Store Reyvow tablets at room temperature (generally 68°F to 77°F or 20°C to 25°C), protected from excessive heat, moisture, and light, and keep the medicine in its original container with the lid tightly closed.

Safety and child access
Keep out of reach of children and pets, and do not use the tablets after the expiration date printed on the package.

Disposal
If you no longer need Reyvow or it is expired, use a local medicine take-back program or follow your pharmacist’s or local waste authority’s instructions; if no take-back option is available, mix tablets (do not crush) with an undesirable substance (such as used coffee grounds or cat litter), seal in a bag or container, and place in household trash.